NCT04053023View on ClinicalTrials.gov

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 27, 2019

Primary Completion Date

November 25, 2019

Study Completion Date

November 25, 2019

Conditions
Cholestasis
Interventions
DRUG

GSK2330672 (linerixibat)

GSK2330672 is available as a tablet with unit dose strength of 45 mg.

DRUG

Obeticholic acid

Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).

Trial Locations (1)

CB2 0GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY